network member

Utah

About Network Member

Enrollment Closed

HCRN-GU16-257

Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing

Matthew D. Galsky

Cancer areas:Bladder

City of Hope

Huntsman Cancer Institute at the University of Utah

Icahn School of Medicine at Mount Sinai

Knight Cancer Institute at Oregon Health & Science University

Penn Medicine Abramson Cancer Center

University of Wisconsin Carbone Cancer Center

USC Norris Comprehensive Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-GU16-287

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer

Matthew D. Galsky

Cancer areas:Bladder Urothelial Carcinoma

Huntsman Cancer Institute at the University of Utah

Icahn School of Medicine at Mount Sinai

Rutgers Cancer Institute

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov